A study in a mouse model of Alzheimer’s disease proposes that degenerating neurons become more excitable because they lose dendrites.
A micro-immunoelectrode allows researchers measure Aβ levels in the interstitial fluid of mice every 30 seconds.
Society for Neuroscience Annual Meeting: A Haven for Basic Science Measuring Rapid Changes in Brain Aβ in Live Mice TREM2 Data Surprise at SfN Annual Meeting Meet GE180: A PET Ligand for Tracking Neuroinflammation? Exosomes: The FedEx of the Nervous ...
Basic preclinical discoveries keep meeting vibrant for neurodegenerative disease researchers from around the world
People who took prescription medications for hypertension were less likely than others to develop amyotrophic lateral sclerosis.
Ready or Not: Stem Cell Therapies Poised to Enter Trials for Alzheimer’s Accelerating the Cure for Alzheimer's Disease through Regenerative Medicine ...
At Duke University, researchers discussed how injected stem cells might be tracked and used to treat neurodegenerative diseases.
Aβ and other pathogenic proteins may cause neurodegenerative disease by spreading throughout the brain like infectious diseases spread through populations, according to a new mathematical model.
Whether by themselves or in the company of mutations that cause frontotemporal dementia, microRNAs may play a hand in driving disease.
At ICFTD, researchers proposed new genes and explored genetic differences that contribute to the vast diversity of FTD clinical presentations.
In debating how C9ORF72 causes neurodegeneration, researchers struggle to connect cell-culture results with divergent patterns of human disease.
Variants in the genome that increase the risk for Alzheimer’s also lower the age of onset.
In a two-year study, a heaping dose of vitamin B did nothing to sharpen cognition in people over 65, casting further doubt on the supplement’s ability to stave off dementia.
FORUM Pharmaceuticals announced that its histone deacetylase inhibitor has passed a Phase 1 trial, and will advance to Phase 2 immediately. It was one of two trials presenting data on active investigational drugs at ICFTD.
Using physiological measurements, researchers are tracing behavior changes in frontotemporal dementia back to crumbling neural circuitry.